Quick Answer
KAZIA THERAPEUTICS LTD reported R&D Expense of $7.33 million for fiscal year 2025.
KAZIA THERAPEUTICS LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.33M | -57.8% |
| 2024 | $17.38M | +11.7% |
| 2023 | $15.56M | -22.8% |
| 2022 | $20.17M | +38.7% |
| 2021 | $14.54M | +53.2% |
| 2020 | $9.49M | +46.6% |
| 2019 | $6.47M | -33.8% |
| 2018 | $9.77M | -12.2% |
| 2017 | $11.14M | +12.6% |
| 2016 | $9.89M | — |
- KAZIA THERAPEUTICS LTD showed a decrease of -57.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, KAZIA THERAPEUTICS LTD’s r&d expense has declined by 26.0% (from $9.89 million to $7.33 million).
- The most recent figure is from KAZIA THERAPEUTICS LTD’s fiscal year 2025 report (Form 20-F), filed with the SEC on November 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: